Multi-center, Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm

Multi-center, Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm

Completed

Phase of Trial:
Phase II

Latest Information Update:24 Dec 2015

At a glance

Most Recent Events

17 Nov 2013
Two of the three planned vanoxerine cohorts have been randomised to 200mg (n=22) 300mg (n=25) and placebo (n=22). The third cohort (400mg) is currently being enrolled according to the abstract preseneted at AHA.

17 Nov 2013
Interim results for the 200 and 300mg cohorts presented at the 86th Annual Scientific Sessions of the American Heart Association.

01 Oct 2013
Status changed from recruiting to completed as reported by ClinicalTrials.gov.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription